A clinical trial of a slow-release formulation of acetylsalicylic acid in patients at risk for preeclampsia.
The formation of thromboxane A2 (TXA2) in maternal and foetal cord serum was measured at birth in eight control patients and in 13 patients taking 100 mg of a slow-release formulation of acetylsalicylic acid. The serum concentrations of TXB2 (a stable end product of TXA2 hydrolysis) in both maternal and cord serum from patients who ingested the acetylsalicylic acid formulation were significantly lower (P < 0.01) than those in control subjects. Acetylsalicylic acid was not detected (< 30 ng ml-1) in maternal plasma from six mothers and in cord plasma from seven foetuses in the acetylsalicylic acid-treated group. The mean cord to maternal plasma concentration ratios for detectable acetylsalicylic acid and salicylate were 0.62 +/- 0.19 (s.d.) (n = 6) and 0.84 +/- 0.16 (n = 13), respectively. We conclude that low doses of acetylsalicylic acid given in a slow-release form to mothers during pregnancy cause depression of TXA2 formation in the foetal blood.
Shen
J
J
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Wanwimolruk
S
S
Wilson
P D
PD
Seddon
R J
RJ
Roberts
M S
MS
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006801:Humans; D007202:Indicators and Reagents; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D012306:Risk; D012459:Salicylates / Q000097:blood; D020156:Salicylic Acid; D013928:Thromboxane A2 / Q000097:blood*
D003692:Delayed-Action Preparations; D007202:Indicators and Reagents; D012459:Salicylates; D013928:Thromboxane A2; D020156:Salicylic Acid; D001241:Aspirin